>
Switch to:

Turning Point Therapeutics Research & Development

: $131.91 Mil (TTM As of Mar. 2021)
View and export this data going back to 2019. Start your Free Trial

This is the expense the company spent on research and development. Turning Point Therapeutics's research and development for the three months ended in Mar. 2021 was $41.26 Mil. Its research and development for the trailing twelve months (TTM) ended in Mar. 2021 was $131.91 Mil.


Turning Point Therapeutics Research & Development Historical Data

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Turning Point Therapeutics Annual Data
Dec17 Dec18 Dec19 Dec20
Research & Development 15.24 21.06 57.94 113.41

Turning Point Therapeutics Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Research & Development Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.77 24.15 32.21 34.28 41.26

Turning Point Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2021 was 24.154 (Jun. 2020 ) + 32.213 (Sep. 2020 ) + 34.275 (Dec. 2020 ) + 41.263 (Mar. 2021 ) = $131.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Turning Point Therapeutics  (NAS:TPTX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.


Turning Point Therapeutics Research & Development Related Terms


Turning Point Therapeutics Research & Development Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)